Influence of 1α,25-dihydroxyvitamin D3 on growth regulation through epidermal growth factor receptor in human breast cancer cell lines

International Journal of Oncology

Volumn 10, Issue 2, 1997, Pages 287-291

  Takeo, Takeshi ^a   Iino, Yuichi ^a   Aoyagi, Hidetada ^a   Horii, Yoshio ^a   Ikeda, Fumihiro ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

1,25(OH)2D3; epidermal growth factor; epidermal growth factor receptor; MCF 7

Indexed keywords

CALCITRIOL; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL; CELL CULTURE; CELL GROWTH; DRUG MECHANISM; HUMAN; HUMAN CELL; ISOTOPE LABELING; PRIORITY JOURNAL; RECEPTOR BINDING;

EID: 0031056153     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Iino Y, Gibson DFC and Jordan VC: Anticstrogen therapy for breast cancer: current strategies and potential causes for therapeutic failures. In: Regulatory Mechanisms in Breast Cancer. Lippman ME and Dickson RB (eds). Kluwer Academic Publishers, Boston pp221-237, 1991.
2. Darbre PD and Dayly RD: Transition of human breast cancer cells from an oestrogen responsive to unresponsive state. J Steroid Biochem Mol Biol 37: 753-763, 1990.
3. Katzenellenbogen BS: Antiestrogen resistance: mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy. J Natl Cancer Inst 83: 1434-1435, 1991.
4. Dayly RJ, King RJB and Darbre PD: Interaction of growth factors during progression towards steroid independence in T-47-D human breast cancer cells. J Cell Biochem 43: 199-211, 1990.
5. Murphy CS, Pink JJ and Jordan VC: Characterization of a receptor-negative, hormone-nonresposive clone derived from a T-47-D human breast cancer cell line kept under estrogen-free conditions. Cancer Res 50: 7285-7292, 1990.
6. Artega CL, Coronade E and Osborne CK: Blockade of epidermal growth factor inhibits transforming growth factor α-induced but not estrogen-induced growth of hormone-dependent human breast cancer. Mol Endocrinol 2: 1064-1069, 1988.
7. Bates SE, Davidson NE, Valverius EM, Freter CE, Dickson RB, Tam JP, Kudloe JE, Lippman ME and Salomon DS: Expression of transforming growth factor and messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its functional significance. Mol Endocrinol 2: 543-555, 1988.
8. Richard J, Sainsbury C, Farndon JR, Needham GK, Malcolm AJ and Harris AJ: Epidermal-growth-factor receptor status as predictor of early recurrence and death from breast cancer. Lancet 20: 1398-1402, 1987.
9. Lee CSL, Hall RE, Alexander IE, Koga M, Shine J and Sutherland RL: Inverse relationship between estrogen receptor and epidermal growth factor receptor mRNA levels in human breast cancer cell lines. Growth Factors 3: 97-103, 1990.
10. Davidson NE, Gelman EP, Lippman ME and Dickson RB: Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol 1: 216-223, 1987.
11. Eisman JA, Koga M, Sutherland RL, Barkla DH and Tutton PJM: Dihydroxyvitamin D3 and the regulation of human cancer cell replication. Proc Soc Exp Biol Med 191: 221-226, 1989.
12. 3 modulation of mammary tumor cell growth in vitro and in vivo. Breast Cancer Res Treat 27: 69-81, 1993.
13. 3 analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 44: 693-702, 1992.
14. 3 analogues: a novel class of potent inhibitors of proliferation and inducer of differentiation of human breast cancer cell lines. Cancer Res 55: 2822-2830, 1995.
15. 3 analogs on MCF-7 human breast cancer cells. Cancer Lett 92: 77-82, 1995.
16. Nakamura T: Establishment and characterization of three human breast cancer cell lines cultured with serum-free medium (in Japanese). Kitakanto Med J 39: 233-245, 1989.
17. Hinegardner TT: An improved fluorometric assay for DNA. Anal Biochem 39: 197-201, 1971.
18. Scatchard RL: The attractions of proteins for small molecules and ions. Ann NY Acad Sci 51: 660-672, 1949.
19. Fitzpatric SL, LaChance MP and Shultz GS: Characterization of epidermal growth factor receptor and action on human breast cancer cells in vitro. Cancer Res 44: 3442-3447, 1984.
20. Cohen S: Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem 237: 1555-1562, 1962.
21. Cohen S and Carpenter S: Human epidermal growth factor: isolation and chemical and biological properties. Proc Natl Acad Sci USA 72: 1317-1321, 1975.
22. Eisman JA, Martin TJ, MacIntyre I and Moseley JM: 1,25-dihydroxyvitamin-D receptor in breast cancer cells. Lancet ii: 1335-1336, 1979.
23. 3. Clin Endocrinol 13: 267-272, 1980.
24. 3 analogue, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 129: 832-837, 1991.
25. 3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res 53: 3712-3718, 1993.
26. 3. Mol Cell Endocrinol 63: 189-198, 1989.
27. 3 increases epidermal growth factor receptor gene expression in BT-20 breast carcinoma cells. Biochem Biophys Res Commun 176: 1-6, 1991.
28. 3 in human breast cancer cells. Cancer Res 48: 2734-2739, 1988.
29. 3 derivatives and breast-tumor cell growth: effect on intracellular calcium and apoptosis. Int J Cancer 61: 806-811, 1995.
30. 3 enhances the expression of transforming growth factor β1 and its latent form binding protein in cultured breast carcinoma cells. Cancer Res 55: 1540-1546, 1995.
31. Hashimoto J, Kikuchi T, Matsumoto T, Nishii Y, Ogata E and Ikeda K: Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted human breast calcinoma and its synergism with tamoxifen. Cancer Res 53: 2534-2537, 1993.
32. 3 analogues and tamoxifen. Cancer Res 54: 5711-5717, 1994.
33. Bower M, Colston KW, Stein RC, Hedley A, Gazet JC, Ford HT and Coombes RC: Topical calcipotriol treatment in advanced brest cancer. Lancet 337: 701-702, 1991.
34. Rotstein S, Glas U, Eriksson M, Pfeiffer P, Hansen J, Söderqvist J, Bandmann U and Strid S: Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patient with bone metastasis - a prospective randomised placebo-controlled multicentre study. Eur J Cancer 28A: 890-893, 1992.
35. Francini G, Gonnelli S, Petrioli R, Conti F, Paffetti P and Gennari C: Treatment of bone metastases with dichloromethylene bisphosphonate. J Clin Oncol 10: 591-598, 1992.
36. Holten-Verzantoot ATV, Bijvoet OLM, Cleton FJ, Hermans J, Kroon HM, Harinck HIJ, Vermery P, Elte JWF, Neijt JP, Beex LVAM and Blijham G: Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet 31: 983-985, 1987.
37. Coleman RE, Woll PJ, Scrivener W and Rubens RD: Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)- 1,1-bisphosphonate (APD). Br J Cancer 58: 621-625, 1988.
38. Morton AR, Cantrill JA, Pillai GV, MacMahon A, Anderson DC and Howell A: Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. Br Med J 297: 772-773, 1988.